Search research articles
Contact Us
Filters
Showing results (71-80 of 91) with videos related to
Page
of 10
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
May 23, 2020
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer
C-G Kaderbhaï, B Coudert, A Bertaut, et al.
British Journal of Cancer
|
October 28, 2010
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
S Guiu, M Gauthier, B Coudert, et al.
Annales De Biologie Clinique
|
April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]
J M Riedinger, N Eche, J P Basuyau, et al.
Breast Cancer Research and Treatment
|
November 4, 2016
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis
Clémentine Jankowski, S Guiu, M Cortet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2012
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
I Le Ray, S Dabakuyo, G Crehange, et al.
British Journal of Cancer
|
January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould, M Gelly, F Penault-Llorca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme
C Twelves, M Campone, B Coudert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer
H Curé, V Chevalier, A Adenis, et al.
The European Respiratory Journal
|
June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
I Borget, J Cadranel, J-P Pignon, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 91) with videos related to
Sort By:
Page
of 10
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
May 23, 2020
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer
C-G Kaderbhaï, B Coudert, A Bertaut, et al.
British Journal of Cancer
|
October 28, 2010
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
S Guiu, M Gauthier, B Coudert, et al.
Annales De Biologie Clinique
|
April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]
J M Riedinger, N Eche, J P Basuyau, et al.
Breast Cancer Research and Treatment
|
November 4, 2016
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis
Clémentine Jankowski, S Guiu, M Cortet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2012
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
I Le Ray, S Dabakuyo, G Crehange, et al.
British Journal of Cancer
|
January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould, M Gelly, F Penault-Llorca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme
C Twelves, M Campone, B Coudert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer
H Curé, V Chevalier, A Adenis, et al.
The European Respiratory Journal
|
June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
I Borget, J Cadranel, J-P Pignon, et al.
Page
of 10